For Nurses

Trelstar was the first intramuscular GnRH agonist indicated for the palliative treatment of advanced prostate cancer. Trelstar offers the unique combination of reliable PSA and testosterone suppression, simple intramuscular administration via MIXJECT, and a low incidence of injection site pain—just 1.7% with the 6-month Trelstar 22.5 mg formulation. Trelstar is also the only GnRH agonist available in one-, three-, and six-month formulations that is stored at room temperature. No need for refrigeration helps make Trelstar preparation easy.

Trelstar.com provides important information and support for nurses who treat patients with advanced prostate cancer. Click on any of the links below to learn more about Trelstar’s testosterone suppression, which is similar to levels achieved with surgical castration; the easy administration of Trelstar with MIXJECT®; and resources to help you care for your patient with advanced prostate cancer.

About Trelstar read more Trelstar Prescription Fulfillment read more
Administering Trelstar with MixJect read more
Patient Care read more Reimbursement and Support read more

Indication

Trelstar® is indicated for the palliative treatment of advanced prostate cancer.

Important Safety Information

The most commonly reported adverse events associated with the use of Trelstar® 22.5 mg included hot flushes (71.7%), erectile dysfunction (10.0%), and testicular atrophy (7.5%) • The most commonly reported adverse events associated with the use of Trelstar® 3.75 mg/Trelstar® 11.25 mg included hot flushes (58.6%/73.0%), skeletal pain (12.1%/13.2%), impotence (7.1%/2.3%), headache (5.0%/6.9%), leg pain (2.1%/5.2%), and edema in legs (0.0%/6.3%) • Trelstar® is contraindicated in women who are or may become pregnant as well as patients who are hypersensitive to triptorelin, other GnRH agonists, or GnRH • Anaphylactic shock, hypersensitivity, and angioedema related to triptorelin administration have been reported • Trelstar® causes an initial transient increase in testosterone levels. Patients may experience the onset or exacerbation of symptoms during this period, including bone pain, neuropathy, hematuria, urethral or bladder outlet obstruction, or spinal cord compression that may contribute to weakness or paralysis with or without fatal complications. Patients with metastatic vertebral lesions and/or urinary tract obstruction should be closely observed. Hyperglycemia and an increased risk of developing diabetes, as well as increased risk of myocardial infarction, sudden cardiac death, and stroke have been reported in men receiving GnRH analogs. Patients should be monitored for blood glucose level and cardiovascular disease, and managed according to current clinical practice

MIXJECT® is a registered trademark of Medimop Medical Projects Ltd.